Provided by Tiger Fintech (Singapore) Pte. Ltd.

ArTara Therapeutics, Inc.

3.34
+0.21506.89%
Post-market: 3.460.1244+3.73%18:46 EDT
Volume:363.30K
Turnover:1.21M
Market Cap:128.67M
PE:-2.05
High:3.43
Open:3.15
Low:3.15
Close:3.12
Loading ...

Promising Potential of Protara Therapeutics’ TARA-002 in Addressing BCG Shortages for NMIBC Treatment

TIPRANKS
·
06 Jun

Protara Therapeutics Inc. Files Initial Beneficial Ownership Statement for William Conkling, Chief Commercial Officer

Reuters
·
05 Jun

BRIEF-Protara Therapeutics Announces Appointment Of William Conkling As Chief Commercial Officer

Reuters
·
03 Jun

Protara Therapeutics Names William Conkling as Chief Commercial Officer

MT Newswires Live
·
03 Jun

Protara appoints William Conkling as Chief Commercial Officer

TIPRANKS
·
03 Jun

Protara Therapeutics Announces Appointment of William Conkling as Chief Commercial Officer

THOMSON REUTERS
·
03 Jun

Press Release: Protara Therapeutics Announces Appointment of William Conkling as Chief Commercial Officer

Dow Jones
·
03 Jun

Director Richard S. Levy Reports Acquisition of Protara Therapeutics Inc. Common Shares

Reuters
·
17 May

Protara Therapeutics’ TARA-002: A Promising Alternative for NMIBC with Strong Efficacy and Safety Profile

TIPRANKS
·
09 May

Protara Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
08 May

BRIEF-Protara Therapeutics Q1 EPS USD -0.29

Reuters
·
08 May

Protara Therapeutics: Cash, Cash Equivalents & Investments of $158 Mln as of Mar 31, Expected to Support Planned Operations Into 2027

THOMSON REUTERS
·
08 May

Protara Therapeutics Q1 Net Income USD -11.914 Million

THOMSON REUTERS
·
08 May

Protara Therapeutics Q1 EPS USD -0.29

THOMSON REUTERS
·
08 May

Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
02 May

Dow Jumps Over 150 Points; Domino's Pizza Posts Upbeat Earnings

Benzinga
·
28 Apr

Protara Therapeutics Price Target Maintained With a $23.00/Share by HC Wainwright & Co.

Dow Jones
·
28 Apr

Protara Therapeutics to Host Conference Call and Webcast to Review Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC on Monday, April 28, 2025

GlobeNewswire
·
23 Apr

Protara Therapeutics Initiated at Sector Outperform by Scotiabank

Dow Jones
·
16 Apr

Scotiabank Initiates Protara Therapeutics at Sector Outperform With $12 Price Target

MT Newswires Live
·
16 Apr